CYTORI THERAPEUTICS DE (CYTX)

Overview Price 3.83 Price Change Today 0.00 (0.00%) P&P rating Zacks Rank 3 - HOLD Open Price $0.00 Previous Close $3.83 Daily Range $0.00 - $0.00 52-Week Range $1.90 - $8.44 Volume 0 Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. Other Resources for CYTX Detailed Quote Earnings Estimates Company Report Interactive Chart Commentary Zacks Blog: Cytomedix Fundamentals Improving September 1, 2011 Zacks Blog: Cytomedix Fundamentals Improving September 1, 2011 Zacks Blog: Cytomedix Fundamentals Improving September 1, 2011 Zacks Blog: Cytomedix Fundamentals Improving September 1, 2011 Zacks Blog: Cytomedix Fundamentals Improving September 1, 2011 Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.   Brokerage Analyst Recommendations 5 Brokerage Firms Covering CYTX   Strong Buy 2 Buy 0 Hold 1 Sell 0 Strong Sell 2 Average Broker Recommendation (ABR): 3   CYTX Ratings: BUY  SELL  HOLD CYTX Consensus Forecasts

Rate this Stock! You haven't rated this stock yet! Ticker Call Buy Sell Analysis Time Frame Week or Less Week to a Month One to Three Months Three to Six Months Six Months to a Year One to Three Years Three Plus Years What The Community Thinks Total Players 5 Buy 1 Sell   Top Buy Analysis BUY: CYTX Company: CYTORI THERAPEUTICS INC Points: -37.75 Start Price: $5.50 Start Date: 07/06/2008 11:07 PM sdminime P&P Score: 72.43 Recs: Control process which extracts stem cells from patients own fat cells to be used on behalf of patients medically. Process/device approved in europe, US approval soon. Co. does not extract stem cells from fetuses. Comments: 0 | Comment More Recent Analysis Top Sell Analysis SELL: CYTX Company: CYTORI THERAPEUTICS INC Points: 59.35 Start Price: $6.14 Start Date: 12/05/2009 10:42 AM BearNekkid P&P Score: 0.48 Recs: Comments: 0 | Comment More Recent Analysis

Blog Posts

User	User Score	Date	Title	Comments	Last Comment
zantriocom	0.00	01/14/10	Zantrio.com Free Daily Stock Picks 1-14-2010	0
Zacks_Analysts	0.00	07/27/11	Analyst Interview - International Stem Cell - Analyst Blog	0
Zacks_Analysts	0.00	11/19/10	Zacks Updates from AHA - Analyst Blog	0
Zacks_Analysts	0.00	11/05/10	Cytori Financial Review - Analyst Blog	0
Zacks_Analysts	0.00	08/25/10	Stem Cell Confusion Creates Opportunity - Analyst Blog	0
Zacks_Analysts	0.00	07/29/10	Initiating Coverage of Aastrom Bio - Analyst Blog	0
Zacks_Analysts	0.00	03/15/10	Optimistic on Cytori Therapeutics - Analyst Blog	0
Zacks_Analysts	0.00	06/30/09	Zacks Analyst Blog Highlights: Cytori Therapeutics, Luminex Corp., Bank of NY Mellon, First Advantage Corporation and First American Corporation - Press Releases	0
Zacks_Analysts	0.00	06/29/09	Cytori's IP and Cash Position Solid - Analyst Blog	0

Pages: [ 1 ]  2  >>

Commentary

BUY: CYTORI THERAPEUTICS INC (CYTX) Start Price: $7.38 Points: -73.37 Created: 02/14/2010 Tissue regeneration technology, uses stemcells derived from patient's own body fat. Being used successfuly in Europe and testd in US now for breast reconstruction. GE provides key technology used with the product. Being tested for heart muscle reconstruction. Videos avalilble at company website. Very large market potential. Comments: 0 | Comment danvee17 Recs:

BUY: CYTORI THERAPEUTICS INC (CYTX) Start Price: $8.02 Points: -75.63 Created: 01/26/2010 CYTX is the bio-tech leader in regenerative medicine. It's stock price doubled in 2009; is expected to double in 2010, and is targeted to reach $40-$50/shrs within a few years. Comments: 0 | Comment play2win2 Recs:

BUY: CYTORI THERAPEUTICS INC (CYTX) Start Price: $8.22 Points: -76.85 Created: 01/24/2010 good things are going on ,stock could be a 5 bagger. Comments: 1 | Comment johnd Recs:

BUY: CYTORI THERAPEUTICS INC (CYTX) Start Price: $5.50 Points: -37.75 Created: 07/06/2008 Control process which extracts stem cells from patients own fat cells to be used on behalf of patients medically. Process/device approved in europe, US approval soon. Co. does not extract stem cells from fetuses. Comments: 0 | Comment sdminime Recs:

SELL: CYTORI THERAPEUTICS INC (CYTX) Start Price: $6.14 Points: +59.35 Created: 12/05/2009 Comments: 0 | Comment BearNekkid Recs:

Picks

Username	P&P Score	Call	Time Frame	Start Date	Start Price	Today (change)	Stock Gain	S&P Gain	Points	Analysis
danvee17		BUY	One to Three Years	02/14/2010	$7.38	$3.86 (-2.77%)	-47.70%	+25.68%	-73.37	view close
play2win2		BUY	One to Three Years	01/26/2010	$8.02	$3.86 (-2.77%)	-51.87%	+23.76%	-75.63	view close
johnd	3.36	BUY	One to Three Years	01/24/2010	$8.22	$3.86 (-2.77%)	-53.04%	+23.81%	-76.85	view close
BearNekkid	0.48	SELL	Three to Six Months	12/05/2009	$6.14	$3.86 (-2.77%)	-37.13%	+22.22%	+59.35
sdminime	72.43	BUY	One to Three Years	07/06/2008	$5.50	$3.86 (-2.77%)	-29.82%	+7.93%	-37.75	view close